Edition:
United States

Alcobra Ltd (ADHD.OQ)

ADHD.OQ on NASDAQ Stock Exchange Global Market

1.14USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$1.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,317
52-wk High
$5.75
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Amir Efrati reports passive stake of 9 pct in Alcobra Ltd
Friday, 24 Feb 2017 05:40pm EST 

Alcobra Ltd : Amir Efrati reports passive stake of 9 percent in alcobra ltd as on Feb. 22, 2017 .Amir Efrati had previously reported passive stake of 7.5 percent in Alcobra Ltd as of Jan. 23, 2017.  Full Article

Alcobra Ltd says pre-ind meeting with FDA held on Alcobra's proprietary abuse-deterrent, amphetamine immediate release (ADAIR) product candidate
Monday, 6 Feb 2017 04:01pm EST 

Alcobra Ltd : Alcobra Ltd says pre-ind meeting with FDA held on Alcobra's proprietary abuse-deterrent, amphetamine immediate release (ADAIR) product candidate .Alcobra Ltd says meeting defined a 505(b)(2) development path, to be funded with existing cash balance, and targeting a 2H 2018 NDA submission.  Full Article

Amir Efrati reports 7.5 pct stake in Alcobra Ltd as of Jan. 23
Thursday, 2 Feb 2017 09:41am EST 

Alcobra Ltd : Amir Efrati reports 7.5 percent stake in Alcobra Ltd as of January 23 - sec filing .Amir Efrati - purchased Alcobra securities based on belief that such securities, when purchased, were undervalued.  Full Article

Alcobra Qtrly loss per share $0.28
Tuesday, 15 Nov 2016 07:30am EST 

Alcobra Ltd : Qtrly loss per share $0.28 . Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S .Alcobra announces third quarter 2016 financial results and provides corporate update.  Full Article

Alcobra reports Q2 loss per share of $0.21
Tuesday, 30 Aug 2016 07:00am EDT 

Alcobra Ltd : Alcobra announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $0.21.  Full Article

Alcobra grants European orphan drug designation for Metadoxine
Tuesday, 19 Jul 2016 08:00am EDT 

Alcobra Ltd : Alcobra granted European orphan drug designation for Metadoxine in fragile X syndrome .European commission has granted orphan drug designation to Metadoxine for treatment of fragile X syndrome within European Union.  Full Article

Alcobra qtrly loss per share $0.18
Monday, 16 May 2016 08:00am EDT 

Alcobra Ltd : Qtrly loss per share $ 0.18 . Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Alcobra announces first quarter 2016 financial results and provides corporate update.  Full Article

Alcobra Ltd prices public offering of ordinary shares
Friday, 13 Nov 2015 08:45am EST 

Alcobra Ltd:Says pricing of its previously announced underwritten public offering of 6,175,000 ordinary shares at an offering price of $6.50 per share.Plans to use the net proceeds from the offering to fund its future clinical development program and for general corporate purposes.  Full Article

Alcobra Ltd announces proposed public offering of ordinary shares
Thursday, 12 Nov 2015 04:05pm EST 

Alcobra Ltd:Intends to offer its ordinary shares in an underwritten public offering.Plans to use the net proceeds from the offering to fund its future clinical development programs and for general corporate purposes.  Full Article

FDA grants fast track designation to Alcobra Ltd's MDX for Fragile X Syndrome
Monday, 21 Sep 2015 08:01am EDT 

Alcobra Ltd:Announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Metadoxine Extended Release (MDX) for the treatment of Fragile X Syndrome.  Full Article

More From Around the Web

BRIEF-Amir Efrati reports passive stake of 9 pct in Alcobra Ltd

* Amir Efrati reports passive stake of 9 percent in alcobra ltd as on Feb. 22, 2017